NEW YORK, May 6, 2021 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health science focused biotechnology company utilizing psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the closing of a $27 million Series A round of funding led by Prime Movers Lab, an investor in breakthrough scientific startups working to revolutionize the world’s most…
